Expanding Clinical Pipelines, Contract Manufacturing Adoption, and Automation-Led Process Innovation Fuel Robust Market Growth Globally.Austin, United States, Feb. 27, 2026 (GLOBE NEWSWIRE) -- ...
What is the current status of cell therapies today? It's an exciting time to be in cell therapy manufacturing and commercialization, particularly in the oncology space. This year alone, we've seen the ...
Adoptive therapies based on CAR/TCR T cells—that is, T cells with an engineered chimeric antigen receptor (CAR) or a T-cell receptor (TCR)—have shown promise for a range of cancers, offering hope to ...
PHC Corporation’s Biomedical Division (Head Office: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereinafter “PHCbi”), a ...
Not all patients respond well to chimeric antigen receptor (CAR) T cell therapies, which reprogram a patient’s own immune cells to recognize and attack cancer. A way to optimize these treatments is to ...
Europe’s battery startups keep hitting the same wall: expensive power, slower scaling, heavy capex, and relentless price ...
Wang tells PV Tech Premium that copper offers a ‘a compelling combination’ of traits to replace silver. Image: AIKO. This Premium article, which was one of the most read Premium articles in 2025, has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results